HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $35 price target.
Needham Reiterates Buy on Stoke Therapeutics, Maintains $25 Price Target
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $25 price target.
Expert Ratings for Stoke Therapeutics
Analysts have provided the following ratings for Stoke Therapeutics (NASDAQ:STOK) within the last quarter: Bullish Somewhat Bullish Indifferent…
Credit Suisse Maintains Outperform on Stoke Therapeutics, Lowers Price Target to $32
Credit Suisse analyst Judah Frommer maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and lowers the price target from $38 to $32.
HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Lowers Price Target to $35
HC Wainwright & Co. analyst Andrew Fein maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $70 to $35.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 160 companies set new 52-week lows.
BrightView Holdings, America’s Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session
Gainers
Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…